-
08-032026
Forlong Biotechnology Announces Successful Completion of GMP Pivotal Batch Production for FL115 (IL-15 Superagonist), Ready to Support Upcoming Phase III Clinical Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)
-
05-272026
Forlong Announces Completion of Phase I Clinical Studies of FL115 Monotherapy (IV): Disease Control for 3 Heavily-pretreated Patients with Advanced Solid Tumors over 12 Months
-
04-222026
Forlong Biotechology to Present Clinical Data from the first-in-human study for FL115 (IL-15 superagonist) in US Patients with Advanced Solid tumors at 2026 ASCO Annual Meeting
-
04-162026
Forlong Biotechology Announced CMC Readiness to Initiate GMP Batch Production to Support upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)
-
03-172026
Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting
-
01-072026
Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 （IL-15 Superagonist）in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA
-
10-312025
Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)
-
10-312025
Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting
-
10-222025
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
-
10-152025
Forlong Biotechology Announces Receiving Milestone Payment as Partner Submits IND for A Protein Therapy using its Proprietary Fbody® Long-acting Technology
-
07-102025
Forlong Biotech Announces CDE Clearance for Phase Ib/II IND of FL115 (IV) Plus PD-1(Sintilimab) in Patients with Advanced Solid Tumors
-
02-152025
Forlong Biotech Announces Dosing First Patient in Phase Ib Trial of FL115 (Intravesical) plus BCG for NMIBC
苏公网安备32050502011888号